Secukinumab in refractory non-infectious anterior uveitis
BackgroundSecukinumab is a monoclonal antibody that selectively neutralizes interleukin-17A and has shown efficacy in the treatment of psoriatic arthritis, psoriasis, and axial spondyloarthritis. Its use in non-anterior non-infectious uveitis is controversial, with evidence generally not supporting...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-02-01
|
| Series: | Frontiers in Ophthalmology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fopht.2025.1491981/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850078936952733696 |
|---|---|
| author | Otto M. Olivas-Vergara Inés Hernanz Pablo E. Borges-Deniz Fredeswinda Romero-Bueno Olga Sanchez-Pernaute Ester Carreño |
| author_facet | Otto M. Olivas-Vergara Inés Hernanz Pablo E. Borges-Deniz Fredeswinda Romero-Bueno Olga Sanchez-Pernaute Ester Carreño |
| author_sort | Otto M. Olivas-Vergara |
| collection | DOAJ |
| description | BackgroundSecukinumab is a monoclonal antibody that selectively neutralizes interleukin-17A and has shown efficacy in the treatment of psoriatic arthritis, psoriasis, and axial spondyloarthritis. Its use in non-anterior non-infectious uveitis is controversial, with evidence generally not supporting its effectiveness in these conditions. However, the role of secukinumab in anterior non-infectious uveitis remains unclear.MethodsCase series. Five patients with biological therapy-refractory non-infectious anterior uveitis who were treated with secukinumab were included.ResultsAll 5 patients experienced a uveitis flare-up during treatment, and secukinumab failed to induce long-term remission in 2 of these patients, who also had uncontrolled systemic disease.ConclusionSecukinumab failed to prevent uveitis flare-up in these patients with biological therapy-refractory disease. Further studies are necessary to determine the potential role of secukinumab in the treatment of anterior uveitis. |
| format | Article |
| id | doaj-art-703c55ecb21845f6a0674e2253f2aab5 |
| institution | DOAJ |
| issn | 2674-0826 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Ophthalmology |
| spelling | doaj-art-703c55ecb21845f6a0674e2253f2aab52025-08-20T02:45:24ZengFrontiers Media S.A.Frontiers in Ophthalmology2674-08262025-02-01510.3389/fopht.2025.14919811491981Secukinumab in refractory non-infectious anterior uveitisOtto M. Olivas-Vergara0Inés Hernanz1Pablo E. Borges-Deniz2Fredeswinda Romero-Bueno3Olga Sanchez-Pernaute4Ester Carreño5Rheumatology Department, Fundación Jiménez Díaz University Hospital, Madrid, SpainOphthalmology Department, Fundación Jiménez Díaz University Hospital, Madrid, SpainRheumatology Department, Fundación Jiménez Díaz University Hospital, Madrid, SpainRheumatology Department, Fundación Jiménez Díaz University Hospital, Madrid, SpainRheumatology Department, Fundación Jiménez Díaz University Hospital, Madrid, SpainOphthalmology Department, Fundación Jiménez Díaz University Hospital, Madrid, SpainBackgroundSecukinumab is a monoclonal antibody that selectively neutralizes interleukin-17A and has shown efficacy in the treatment of psoriatic arthritis, psoriasis, and axial spondyloarthritis. Its use in non-anterior non-infectious uveitis is controversial, with evidence generally not supporting its effectiveness in these conditions. However, the role of secukinumab in anterior non-infectious uveitis remains unclear.MethodsCase series. Five patients with biological therapy-refractory non-infectious anterior uveitis who were treated with secukinumab were included.ResultsAll 5 patients experienced a uveitis flare-up during treatment, and secukinumab failed to induce long-term remission in 2 of these patients, who also had uncontrolled systemic disease.ConclusionSecukinumab failed to prevent uveitis flare-up in these patients with biological therapy-refractory disease. Further studies are necessary to determine the potential role of secukinumab in the treatment of anterior uveitis.https://www.frontiersin.org/articles/10.3389/fopht.2025.1491981/fullsecukinumabanterior uveitisuveitisspondyloarthritispsoriatic arthritis |
| spellingShingle | Otto M. Olivas-Vergara Inés Hernanz Pablo E. Borges-Deniz Fredeswinda Romero-Bueno Olga Sanchez-Pernaute Ester Carreño Secukinumab in refractory non-infectious anterior uveitis Frontiers in Ophthalmology secukinumab anterior uveitis uveitis spondyloarthritis psoriatic arthritis |
| title | Secukinumab in refractory non-infectious anterior uveitis |
| title_full | Secukinumab in refractory non-infectious anterior uveitis |
| title_fullStr | Secukinumab in refractory non-infectious anterior uveitis |
| title_full_unstemmed | Secukinumab in refractory non-infectious anterior uveitis |
| title_short | Secukinumab in refractory non-infectious anterior uveitis |
| title_sort | secukinumab in refractory non infectious anterior uveitis |
| topic | secukinumab anterior uveitis uveitis spondyloarthritis psoriatic arthritis |
| url | https://www.frontiersin.org/articles/10.3389/fopht.2025.1491981/full |
| work_keys_str_mv | AT ottomolivasvergara secukinumabinrefractorynoninfectiousanterioruveitis AT ineshernanz secukinumabinrefractorynoninfectiousanterioruveitis AT pabloeborgesdeniz secukinumabinrefractorynoninfectiousanterioruveitis AT fredeswindaromerobueno secukinumabinrefractorynoninfectiousanterioruveitis AT olgasanchezpernaute secukinumabinrefractorynoninfectiousanterioruveitis AT estercarreno secukinumabinrefractorynoninfectiousanterioruveitis |